Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CleanSpace HoldingsASX:CSX 27 Debt-to-EBITDA is 0.35 as of Dec. 2025. GuruFocus rates ASX:CSX with a GF Score™ of 27/100 and a GF Value™ of A$0.55 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 467 Medical Devices & Instruments companies, CleanSpace Holdings ranks better than 67.45% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for CleanSpace Holdings's Debt-to-EBITDA or its related term are showing as below:
ASX:CSX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -96.51 Med: -0.38 Max: 0.62
Current: 0.62
During the past 6 years, the highest Debt-to-EBITDA Ratio of CleanSpace Holdings was 0.62. The lowest was -96.51. And the median was -0.38.
ASX:CSX's Debt-to-EBITDA is ranked better than 67.45% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs ASX:CSX: 0.62
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
CleanSpace Holdings Debt-to-EBITDA Related Terms
CleanSpace Holdings Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for CleanSpace Holdings's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CSX vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, CleanSpace Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CleanSpace Holdings Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CleanSpace Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CleanSpace Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
CleanSpace Holdings (ASX:CSX) has a Debt-to-EBITDA of 0.35 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CleanSpace Holdings. According to the industry distribution chart, CleanSpace Holdings ranks #152 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 32.5%.
Is CleanSpace Holdings' Debt-to-EBITDA too high?
CleanSpace Holdings' current Debt-to-EBITDA is 0.35. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.57. CleanSpace Holdings' value of 0.35 is 77.7% below this industry median. Based on the distribution chart, CleanSpace Holdings ranks #152 out of 467 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, CleanSpace Holdings has a GF Score™ of 27/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CleanSpace Holdings' Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CleanSpace Holdings ranks #152 out of 467 companies for Debt-to-EBITDA. This puts CleanSpace Holdings in the upper half of its industry. The industry median Debt-to-EBITDA is 1.57. CleanSpace Holdings' value of 0.35 is 77.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CleanSpace Holdings's current Debt-to-EBITDA of 0.35 is 77.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CleanSpace Holdings. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CleanSpace Holdings's current Debt-to-EBITDA is 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CleanSpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, CleanSpace Holdings (ASX:CSX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.55, compared to a current price of A$0.40 — trading 28.2% below its estimated fair value. The current Debt-to-EBITDA is 0.35 and 77.7% below the Medical Devices & Instruments industry median of 1.57. CleanSpace Holdings' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For CleanSpace Holdings (ASX:CSX), the current Debt-to-EBITDA is 0.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CleanSpace Holdings (ASX:CSX) Overvalued in 2026?
Based on GuruFocus' analysis, CleanSpace Holdings stock appears to be undervalued.
The current stock price of A$0.40 is trading 28.2% below its estimated GF Value™ of A$0.55.
GuruFocus considers CleanSpace Holdings to be Modestly Undervalued.
Key valuation signals for ASX:CSX:
Debt-to-EBITDA: 0.35
GF Value™: A$0.55 vs. price of A$0.40 (28.2% below fair value)
Industry Position: 77.7% below the Medical Devices & Instruments median (#152 of 467)
No single metric tells the full story. See the ASX:CSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CleanSpace Holdings Ltd manufactures and sells respirators and related products and services. Its products include Compare, CleanSpace HALO, CleanSpace ULTRA, Masks, Filters, and Compatible Products. The company's operating segment is based on regions that include, Europe, Asia, and North America, and the majority of its revenue is generated from Europe.
27GF Score
Get the complete analysis for ASX:CSX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CSX has been successfully added to your 
